Hello , I am considering using the XTEN linker (SESATPES) in a Cas9 fusion protein I may later want to sell. I´ve seen XTEN refered to as Amunix XTEN. I´ve read some patents about XTEN like these ones:
https://patents.google.com/patent/US20150037359A1/en
https://patents.google.com/patent/EP2552967A2/en
and as far as I could tell they don´t seem to apply to simply using SESATPES sequence as a linker sequence in a fusion a protein , but if someone with knowledge in this field could provide me information about if there any limitations or restrictions that I should be aware of when using the XTEN linker in a fusion protein for commercial use I would greatly appreciate it.
Thank you for your input.
I think you have answered your own question. If the patents are still valid, then yes it is proprietary in some countries.
Also there is this news article about them having made a licensing agreement over use of the technology: https://www.fiercepharma.com/drug-delivery/amunix-announces-licensing-agreement-for-its-proprietary-xten-technology.
- Badges
- Science topic